✦ LIBER ✦

Cisplatin–paclitaxel improves progression-free survival compared with cisplatin–cyclophosphamide in advanced epithelial ovarian cancer

✍ Scribed by Robert F. Ozols

Book ID: 119981188
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 192 KB
Volume: 2
Category: Article
ISSN: 1363-4054
DOI: 10.1054/ebon.2000.0083

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin–Paclitaxel–Cyclophosphamide wi

Cisplatin–Paclitaxel–Cyclophosphamide with G-CSF in Primary Advanced Epithelial Ovarian Cancer

✍ James Fanning; Michael Colgrove; Garth Phibbs 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Cisplatin–paclitaxel treatment for advan

Cisplatin–paclitaxel treatment for advanced ovarian cancer resulted in longer survival than cisplatin–cyclophosphamide

✍ Franco Muggia 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 251 KB

Cisplatin or carboplatin plus paclitaxel

Cisplatin or carboplatin plus paclitaxel for advanced ovarian cancer had similar rates of progression free survival

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Cyclophosphamide and Cisplatin Compared

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

✍ McGuire, William P.; Hoskins, William J.; Brady, Mark F.; Kucera, Paul R.; Partr 📂 Article 📅 1996 🏛 Massachusetts Medical Society 🌐 English ⚖ 123 KB

Long-term results of a randomized trial

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Moderately high-dose carboplatin with pa

Moderately high-dose carboplatin with paclitaxel and intraperitoneal cisplatin improves progression-free survival but has higher toxicity than standard intravenous cisplatin and paclitaxel for small volume ovarian cancer

✍ Mario De Lena 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB